Porton Pharma Solutions Ltd. (300363.SZ) has released its third quarter report for 2025, revealing that its revenue for the first three quarters amounted to CNY 2.544 billion, representing a year-on-year increase of 19.72%. The net profit attributable to shareholders of the listed company reached CNY 79.91 million, up 138.71% compared to the previous year. The net profit attributable to shareholders, excluding non-recurring gains and losses, was CNY 53.68 million, marking a year-on-year growth of 125.14%. The basic earnings per share stood at CNY 0.15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments